Recent events
Recent events tied to this brand in public sources.
Back to profile52 entries · Page 2 of 3
2021
Johnson & Johnson agrees to $230 million New York opioid settlement
Johnson & Johnson agreed to pay about $230 million to resolve claims by New York that it helped fuel the opioid crisis. The agreement removes the company as a defendant in a broader opioid trial; J&J did not admit liability or wrongdoing.
2021
Lawsuit filed over DePuy Attune Knee System
A plaintiff and his family filed suit against DePuy Orthopedics and Johnson & Johnson, alleging defects and other product-liability claims concerning an implanted Attune Knee System.
2021
Johnson & Johnson reports 2020 earnings
Johnson & Johnson released its fourth-quarter and full-year 2020 financial results. Full-year revenue was $82.584 billion, up 0.6%, while adjusted net income declined 8.1% to $21.433 billion.
2020
Former Johnson & Johnson executive files discrimination lawsuit
Former Johnson & Johnson executive Gina Bilotti filed a lawsuit against the company alleging sex and gender discrimination, verbal abuse, and retaliation. The allegations are reported as claims in the lawsuit, not as established findings.
2020
Oregon reaches $5.5 million settlement with Johnson & Johnson
Oregon announced a $5.5 million settlement with Johnson & Johnson and its subsidiary Ethicon over alleged deceptive marketing of transvaginal surgical mesh devices. The settlement requires court approval to become final.
2020
Johnson & Johnson announces agreement to acquire Momenta
Johnson & Johnson announced a definitive agreement to acquire Momenta for $6.5 billion in cash. The transaction was expected to close in the second half of 2020; Momenta would continue operating independently until then.
2020
Missouri appeals court upholds verdict against Johnson & Johnson and reduces damages
A Missouri appeals court rejected Johnson & Johnson's bid to throw out a jury verdict in favor of 22 women who blamed their ovarian cancer on its baby powder and other talc products, while reducing the damages award from $4.69 billion to $2.12 billion. The article reports the claims; it does not establish that the products caused the cancer.
2020
Missouri appeals court upholds Johnson & Johnson talc verdict and reduces damages
A Missouri appeals court rejected Johnson & Johnson's bid to overturn a jury verdict in favor of women who blamed their ovarian cancer on its baby powder and other talc products, while reducing damages to $2.12 billion. The court said plaintiffs had proven that J&J and an affiliate concealed that talc products contained asbestos and downplayed safety hazards. J&J said it would appeal and maintained that its talc was safe and asbestos-free.
2020
Johnson China receives multiple employer-brand awards
Johnson China was recognized with multiple employer-brand awards, including a place in Universum's 2020 Most Attractive Employers in China list, a Zhaopin campus-recruitment case award, and 51job's 2020 Most Popular Employer among Chinese University Students award.
2020
Johnson & Johnson announced plans to discontinue skin-lightening products
Johnson & Johnson said it would soon remove its skin-lightening products from sale in Asia and the Middle East and would not manufacture them in the future, after criticism that Neutrogena and Clean & Clear products promoted lighter skin as preferable.
2020
Johnson & Johnson removes talc-based baby powder from U.S. sales
Legal-Bay reported that Johnson & Johnson had removed its talc-based baby powder from its sales line in the United States. The article notes that claimants alleged the product caused ovarian cancer and that Johnson & Johnson denied the accusations.
2020
Johnson & Johnson announces discontinuation of talc-based baby powder in the US and Canada
Johnson & Johnson announced that it would discontinue talc-based baby powder in the United States and Canada, with existing stocks to be sold until depleted. The company said the product would remain on sale in other markets.
2020
Johnson & Johnson reaches $3.9 million West Virginia settlement
West Virginia Attorney General Patrick Morrisey reached a $3.9 million settlement with Johnson & Johnson and specialty corporations to resolve allegations of unlawful, unfair and deceptive marketing of surgical-mesh devices and hip-replacement systems. Johnson & Johnson and its specialty corporations denied the allegations.
2020
Emergent BioSolutions partners with Johnson & Johnson on vaccine manufacturing
Emergent BioSolutions announced a $135 million partnership with Johnson & Johnson to provide drug-substance manufacturing and contract-development services supporting creation of a coronavirus vaccine.
2020
Johnson & Johnson and Apple open Heartline Study enrollment
Johnson & Johnson, in collaboration with Apple, announced that enrollment had opened for the Heartline Study, which will explore whether the Heartline app on iPhone and heart-health features on Apple Watch can improve health outcomes, including reducing stroke risk through earlier detection of atrial fibrillation.
2020
Johnson & Johnson expands US coronavirus research collaboration
Johnson & Johnson expanded its collaboration with BARDA and the US Department of Health & Human Services to screen existing antiviral molecules for compounds that may work against COVID-19. Janssen will also work with Belgium's Rega Institute for Medical Research as part of the expanded collaboration.
2020
Johnson & Johnson China wins 2019 Outstanding Contribution to Innovation Award
Johnson & Johnson China received the 2019 Outstanding Contribution to Innovation Award at the 2019 Corporate Social Responsibility Case Selection and Summit Forum.
2020
Washington state sues Johnson & Johnson over opioid marketing
Washington state sued Johnson & Johnson, alleging that it used deceptive marketing to claim its drugs were effective for pain and unlikely to cause addiction. The lawsuit also named subsidiary Janssen Pharmaceutical Inc.; Janssen said its marketing was appropriate and responsible.
2020
Washington state sues Johnson & Johnson over opioid marketing
Washington state sued Johnson & Johnson, alleging that it used deceptive marketing to claim its drugs were effective for treating pain and unlikely to cause addiction. The lawsuit alleges violations of the state's Consumer Protection Act, negligence, and public nuisance.
2020
Pulmatrix announces licensing and development agreement with Johnson & Johnson Lung Cancer Initiative
Pulmatrix announced a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson, under which the initiative gains an option to access a portfolio of narrow-spectrum kinase inhibitors for development in lung cancer interception.